Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus NephritisBusiness Wire • 04/01/24
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical HighlightsBusiness Wire • 03/25/24
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational ConferenceBusiness Wire • 03/22/24
Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac DiseaseBusiness Wire • 12/21/23
Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of RheumatologyBusiness Wire • 11/13/23
Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical UpdatesBusiness Wire • 11/08/23
Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of NephrologyBusiness Wire • 11/06/23
Equillium Announces Abstracts Accepted for Presentation at the 2023 Annual Meetings of the American Society of Nephrology and the American College of RheumatologyBusiness Wire • 10/19/23
Equillium Announces Preclinical Data from New Orally Deliverable Multi-Cytokine Inhibitor in Presentation at the 18th Annual Peptide Therapeutics SymposiumBusiness Wire • 10/16/23
Equillium to Present at the Cantor Fitzgerald Global Healthcare & LD Micro Main Event ConferencesBusiness Wire • 09/20/23
Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor ConferenceBusiness Wire • 08/30/23
Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical UpdatesBusiness Wire • 08/09/23
Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational ConferencesBusiness Wire • 06/01/23
Equillium Announces Poster Presentation at the Annual Meeting of The American Association of ImmunologistsBusiness Wire • 05/15/23
Equillium: A Negative EV Biotech With Compelling Programs And Cash 'Til At Least 2025; Worth A LookSeeking Alpha • 05/12/23